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Vancomycin has been used as the last resort in the clinical treatment of serious
Staphylococcus aureus infections. Vancomycin-intermediate S. aureus (VISA) was
discovered almost two decades ago. Aside from the vancomycin-intermediate
phenotype, VISA strains from the clinic or laboratory exhibited common characteristics,
such as thickened cell walls, reduced autolysis, and attenuated virulence. However, the
genetic mechanisms responsible for the reduced vancomycin susceptibility in VISA are
varied. The comparative genomics of vancomycin-susceptible S. aureus (VSSA)/VISA
pairs showed diverse genetic mutations in VISA; only a small number of these mutations
have been experimentally verified. To connect the diversified genotypes and common
phenotypes in VISA, we reviewed the genetic alterations in the relative determinants,
including mutations in the vraTSR, graSR, walKR, stk1/stp1, rpoB, clpP, and cmk
genes. Especially, we analyzed the mechanism through which diverse mutations mediate
vancomycin resistance. We propose a unified model that integrates diverse gene
functions and complex biochemical processes in VISA upon the action of vancomycin.
Keywords: vancomycin intermediate Staphylococcus aureus, vancomycin, genetic mechanisms, genotypes,
molecular events
INTRODUCTION
Staphylococcus aureus is a successful human pathogen because of its metabolic versatility and
its ability to adapt to host defensive stress (Didelot et al., 2016). This pathogen can cause mild
infections and life-threatening diseases, including skin and soft tissue infections, bacteremia,
pneumonia, endocarditis, sepsis, and toxic shock syndrome (Dayan et al., 2016). Unfortunately,
a licensed vaccine is unavailable for S. aureus infections. The optimal choice for treatment of
S. aureus infections is the employment of antibiotics. However, antimicrobial resistance in S.
aureus has become a major public health threat. The first antibiotic penicillin was discovered by
Alexander Fleming in 1928 based on the susceptibility of S. aureus; subsequently, penicillin was
clinically applied in a large scale during the early 1940s. After several years, the penicillin-resistant
S. aureus (PRSA) was characterized in hospitals in the mid-1940s. PRSA strains usually carry a
plasmid-encoded penicillinase, which can hydrolyze the β-lactam ring of penicillin to inactivate its
antimicrobial activity. PRSA strains become pandemic by the early 1950s and were significantly
controlled by the introduction of β-lactamase-resistant methicillin into clinic in 1959. However,
the first methicillin-resistant S. aureus (MRSA) strain was quickly generated and isolated in 1961
then spreaded globally. MRSA strains are inherently resistant to virtually all β-lactam antibiotics,
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including penicillins, cephalosporins, and carbapenems. The
emergence of MRSA resistance is the horizontal gene transfer of
the mecA gene, which encodes an alternative penicillin binding
protein 2a (PBP2a) with low-affinity to β-lactam antibiotics.
With complicated evolution, MRSA has become a so-called
“superbug” that has acquired resistance to multiple drugs, from
penicillin/methicillin to quinolone and vancomycin (Nordmann
et al., 2007).
Vancomycin is a cationic glycopeptide antibiotic derived from
the organism Amycolatopsis orientalis (previously known as
Streptomyces orientalis or Nocardia orientalis). Vancomycin was
first discovered by Edmund Kornfield (working at Eli Lilly) in
1953 and approved by the Food and Drug Administration of
the United States in 1958 because of the rapid development of
penicillin resistance by staphylococci (Levine, 2006). However,
due to the ototoxicity and nephrotoxicity caused by the
presence of impurities and the development of other effective
antibiotics, vancomycin was relegated to a second-line antibiotic
in the 1960s and 1970s (Moellering, 2006). Vancomycin kills
bacteria by binding to the C-teminal D-Ala–D-Ala residues
of the peptidoglycan precursor lipid II in the cytoplasmic
membrane to form a stable, non-covalent complex, which
prevents the use of the precursor for cell wall synthesis (Figure 1).
The steric hindrance imparted by vancomycin may further
inhibit the glycosyltransferase and transpeptidase activities
of penicillin-binding proteins (PBPs) (Kahne et al., 2005).
Clinically, vancomycin is used for S. aureus infections and
for infections caused by Streptococcus pneumoniae, Clostridium
difficile, Enterococcus species, and so on. The increasing burden of
MRSA and other Gram-positive bacterial infections in hospitals
led to the increasing use of vancomycin worldwide since the
1980s (Levine, 2006). From 1980s to present, vancomycin is
one of the last remaing antibiotics to which most of the MRSA
and other multiple drug-resistant Gram-positive bacteria were
still reliably susceptible. Moreover, vancomycin is used to treat
osteomyelitis, bacteremia, and endocarditis empirically or when
MRSA is deemed a possible cause (Rubinstein and Keynan,
2014). However, vancomycin-resistant Enterococcus (VRE) was
first reported in 1986 in Europe then in the USA in 1987
(Murray, 2000) (Figure 2). S. aureus clinical isolates with reduced
vancomycin susceptibility, such as the vancomycin-intermediate
resistance S. aureus (VISA) strain Mu50 (MIC = 8 µg/mL)
and the heterogeneous VISA (hVISA) strain Mu3 (MIC =
3 µg/mL), were first reported in Japan in 1997 (Hiramatsu
et al., 1997a,b) then reported globally. VISA usually exhibits
a low level of resistance, as defined by a vancomycin MIC
from 4 to 8 µg/mL, although laboratory-derived VISA strains
with vancomycin MICs of 32–100 µg/mL were achieved by
in vitro mutagenesis (Berscheid et al., 2014; Ishii et al., 2015).
Furthermore, the first vancomycin-resistant S. aureus (VRSA)
isolate MI-1, with an MIC of 128 µg/mL, was recovered in 2002
from the foot wound of a diabetic patient who had received
long-term vancomycin therapy and also had a VRE isolate.
VRSA is a rare, multidrug-resistant bacterial strain of public
health concern. Since its emergence in the USA in 2002, 36 VRSA
strains have been reported, 14 from the USA (Limbago et al.,
2014; Walters et al., 2015), 16 from India, 3 from Iran, 1 from
FIGURE 1 | The mode of action of vancomycin in S. aureus. By binding
to the C-teminal D-Ala-D-Ala residues of the pentapeptide, vancomycin
inhibits the cross bridge formation between pentapeptide and pentaglycine.
GlcNAc, N-acetylglucosamine; MurNAc, N-Acetylmuramic acid.
Pakistan (Moravvej et al., 2013), 1 form Portugal (Melo-Cristino
et al., 2013), and 1 from Guatemala (Antony, 2014). VRSA arises
when vancomycin resistance genes (e.g., the vanA operon, which
codes for enzymes that result in modification or elimination of
the vancomycin-binding site) from VRE are transferred to S.
aureus. The vanA gene cluster is often located in the plasmid-
borne transposon Tn1546, which can transfer from vancomycin-
resistant Enterococcus faecalis to S. aureus and produce a VRSA
isolate (Zhu et al., 2013). The mechanism for VRSA resistance is
well-characterized. The coded product enables VRSA to replace
the D-Ala–D-Ala terminal dipeptide with D-Ala–D-Lac dipeptide,
thereby altering the binding target of vancomycin and often
mediating high level resistance to vancomycin. Although VRSA
may have been underestimated (Moravvej et al., 2013), the
limited cases of VRSA suggest that vanA-mediated vancomycin
resistance is significant but has not evolved or quickly spread;
this trend is probably caused by the high fitness cost imparted by
vanA-type transposon (Foucault et al., 2009). By contrast, VISA
or hVISA isolates have been characterized from many countries
around the world, including United States, France, Australia,
Scotland, Brazil, Japan, South Korea, China, and other countries
(Howden et al., 2010; Zhang et al., 2013). A retrospective
study found that hVISA emerged before the introduction of
vancomycin in Japan in 1990 (Yamakawa et al., 2012). Two
other retrospective studies also revealed that the emergence of
hVISA or VISA isolates in the USA or in Europe can be dated
back to the mid or late 1980s (Rybak et al., 2005; Robert et al.,
2006). Pulsed field gel electrophoresis and multilocus sequence
typing found that VISA strains were not clonal. Most VISA were
reported to evolve from hospital associated MRSA; mainly from
clonal complex 5 or 8, in particular ST5 and ST239, however,
the community associated MRSA clone USA300-derived and
methicillin-susceptible S. aureus (MSSA)-derived VISA are also
reported (Pillai et al., 2009; Gardete et al., 2012). In recent years,
many studies also revealed that there is a vancomycin MIC creep
inmany countries but not consistently observed in different areas
(Sader et al., 2009; Reynolds et al., 2012; Zhuo et al., 2013). The
hVISA strains account for up to 26% of MRSA isolates in Japan
(Schwaber et al., 2003), while in an Australian institute, the rate of
Frontiers in Microbiology | www.frontiersin.org 2 October 2016 | Volume 7 | Article 1601
Hu et al. Molecular Events in VISA
FIGURE 2 | Timeline indicates the year in which an event occurred or was reported. The increased use of vancomycin in the USA, France, Italy, Germany, the
United Kingdom, and the Netherlands was shown as tons of vancomycin in the y-axis, which was modified from reference Levine (2006).
hVISA is almost 50% (Horne et al., 2009). The high rate of hVISA
paved the way for the evolution of VISA.
Aside from the vancomycin-intermediate phenotype, VISA
strains exhibit common characteristics, such as thickened cell
walls, reduced autolysis, and attenuated virulence (Howden
et al., 2011). Understanding the molecular mechanisms for
reduced vancomycin susceptibility in VISA has been rapidly
moved forward by whole genome sequencing of vancomycin-
susceptible S. aureus (VSSA)/VISA pairs or series (Howden
et al., 2011). The mechanisms underlying VISA resistance may
be complicated; diverse mutations occurred in VISA have been
identified, but only a small number of mutations in several genes
have been experimentally verified. In this review, we summarize
the phenotypic features associated with VISA and thoroughly
catalog the diverse mutations in VISA, especially those that
have been experimentally characterized. Specifically, we reviewed
and analyzed four categoris of genetic mutations occurred in
VISA, including mutations in cell wall synthesis, hydrolysis, or
remodeling genes, in metabolic genes, in transcription regulatory
genes, and in post-translational modification genes. Based on
these analyses, we connected the genetic mutations in different
genes, biochemical functions of the cognate proteins, and
key metabolic pathways that contribute to the promotion of
vancomycin resistance in VISA.
COMMON FEATURES OF VISA
VISA exhibits several common phenotypic changes compared
with VSSA; these features include increased cell wall thickness,
reduced autolysis, decreased activity of the staphylococcal global
regulator Agr, reduced lysostaphin susceptibility, and changes in
cell wall teichoic acids (Nannini et al., 2010).
Thickened Cell Walls with Low
Cross-Linking
Bacterial cell walls play important roles in the protection of
viable cells, as well as the infectivity and pathogenicity of
Gram-positive and Gram-negative bacteria. Staphylococcal cell
walls are composed of murein, teichoic acids, and wall-associated
surface proteins, with a thickness of ≈20 nm (Dmitriev et al.,
2004). The stress-bearing murein of S. aureus consists of glycan
strands, which are composed of N-acetylglucosamine (GlcNAc)
and N-acetylmuramic acid (MurNAc) residues that form β-(1–
4)-linked disaccharide repeating units. The carboxyl group of
each MurNAc residue of the murein is amidated by the stem
pentapeptide L-Ala–D-Gln–L-Lys–D-Ala–D-Ala; a pentaglycine
bridge branches with the ε-amino group of the L-Lys residue
of pentapeptide and the carboxyl group on the D-Ala terminus
of the other pentapeptide to provide a high degree of murein
cross-linking. The process of murein cross-linking is catalyzed by
PBP2/PBP4 proteins.
Mu50 was the first VISA isolated from the purulent discharge
at the sternal incision site of a 4 month-old male infant who
underwent heart surgery for pulmonary atresia; its cell wall
appeared to be twice as thick as that of control strains under an
electron microscope (Hiramatsu et al., 1997b). The thickness of
the cell wall was associated with the vancomycin resistance in
VISA. Cui et al. (2003) demonstrated that cell wall thickening is a
common feature of VISA isolates. Although the general principle
of murein structural organization seems simple, the muropeptide
composition of the staphylococcal cell wall appears very complex
because the catalysis of murein cross-linking with PBPs is dose-
dependent and often produces a distinctive degree of murein
cross-linking. Hanaki et al. (1998) found that the incorporation of
14C-lablled GlcNAc into the cell wall and the intracellular murein
monomer precursor was increased in Mu50; the activated cell
wall synthesis and the resulting thickened cell walls might be a
prerequisite for vancomycin resistance in VISA. Sieradzki and
Tomasz (2003) revealed that VISA isolates in the JH serial strains
produced thickened cell walls and upregulated the PBP2 protein
level, similar to a Chinese VISA XN108 (Zhang et al., 2013).
However, the protein level of PBP4was drastically reduced, which
decreased the cross-linking of VISA cell walls.
The thickened cell wall and decreased murein cross-linking
were proposed to be significant for vancomycin resistance in
VISA. The actual target of vancomycin is the free D-Ala–D-Ala
Frontiers in Microbiology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 1601
Hu et al. Molecular Events in VISA
terminal of the pentapeptide. The last D-Ala should be
hydrolyzed by PBP4, and the pentaglycine of a murein monomer
could be branched by PBP2 to finish the cross-linking. The
cell wall of S. aureus usually has ≈20% of its peptidoglycan
components that are not crosslinked, which produced an
appropriate amount of free D-Ala–D-Ala residues in the cell
wall. The thickened cell wall of a VISA usually has decreased
cross-linking in its peptidoglycan, which will increase the amount
of free D-Ala–D-Ala residues that allow the “capture” of more
vancomycin molecules to protect VISA from the antibiotic
(Sieradzki and Tomasz, 2003). Furthermore, the Gln-non-
amidated murein monomer is increased in VISA, which is a
poor substrate for PBPs but has a greater binding affinity for
vancomycin than Gln-amidated muropeptide (Cui et al., 2000).
Vancomycin has to pass through the peptidoglycan layers to
reach the lipid II-bound muropeptide, which accumulates in
the division septum. Thus, most vancomycin molecules might
be trapped by the free D-Ala–D-Ala residues in the thickened
cell walls of VISA. The cell wall thickness and vancomycin
resistance are strongly correlated (Cui et al., 2000). Fluorescence
microscopy shows that VISA strains can trap more vancomycin
molecules than VSSA strains, thus less vancomycin molecules
can arrive at the active cell wall synthesis site (Pereira et al.,
2007). The thickened cell wall of Mu50 consumes more than
2.8 times of vancomycin than VSSA (Cui et al., 2000). After
binding with vancomycin molecules, the structure of the outer
layers of VISA thickened peptidoglycan is more compact to
prevent further penetration of vancomycin molecules. This so-
called “vancomycin clogging effect” might also contribute to
vancomycin resistance in VISA (Cui et al., 2006).
Decreased Autolysis
Autolysis occurs in a wide variety of bacteria and is catalyzed
by their own autolytic enzymes to cleave specific bonds in
the bacterial cell wall peptidoglycan. In S. aureus, several
muramidases and amidases, such as lysostaphin, AltA, and
LytM, participate in autolysis. The autolytic activity could be
determined by whole-cell assays in 0.05M Tris–HCl (pH 7.2)
containing 0.05% Triton X-100 or purified cell wall assays to
retain the autolytic activities of the crude cell walls (Utaida
et al., 2006). VISA strains often express reduced autolytic activity
vs. that of VSSA (Howden et al., 2010). Mu50 was shown to
be deficient in autolytic activity when whole-cell assays were
conducted (Utaida et al., 2006). Correspondingly, the expression
level of autolysins was down-regulated in VISA. The decreased
autolysis in VISA may contribute to the cell wall thickening,
thereby preventing vancomycin from reaching its action site.
Decreased Virulence
An S. aureus strain may suffer severe fitness cost upon
developing resistance to certain antibiotics, such as resistance
to ciprofloxacin or gentamicin; this fitness cost could be a
disadvantage for its pathogenesis or clonal spreading in a given
region (Shang et al., 2016). Several animal models were used to
evaluate the virulence of VISA. In Galleria mellonella, a model
insect, clinical VISA isolates have reduced virulence compared
with their parental strains (Peleg et al., 2009; Howden et al.,
2011). Furthermore, a VISA isolate showed reduced infectivity
and rapid blood clearance compared with its parental strain in
a rat endocarditis model (Majcherczyk et al., 2008). Another
VISA isolate had attenuated virulence and lost the capacity
to generate liver abscesses and tissue necrosis in a mouse
sepsis model (Cameron et al., 2012). S. aureus produces tens
of virulence factors for pathogenesis; VISA transcriptomic data
were generally consistent with decreased virulence (Gardete et al.,
2012). Hattangady et al. (2015) demonstrated that genes encoding
secreted proteases and hemolysins were generally downregulated
in two VISA strains vs. their progenitor VSSA strains. A VISA
strain named SG-R, belonging to the MRSA clone USA300,
showed massive downregulation in the transcription of virulence
determinants, including seven of the major virulence genes of S.
aureus (Gardete et al., 2012). Importantly, the transcription level
of a virulence gene was restored when the vancomycin-resistant
isolate SG-R was phenotypically “converted” to vancomycin
susceptibility by the genetic complementation experiments
(Gardete et al., 2012). These data indicate that the decreased
virulence in VISA is associated with the same mutated gene
responsible for the reduced vancomycin susceptibility. VISA
strains with decreased or attenuated virulence fail to cause
acute infections; however, decreased or attenuated virulence may
represent a “stealth” strategy to evade host immune surveillance
and promote clinical persistence (Gardete et al., 2012).
DIVERSE MUTATIONS IDENTIFIED IN VISA
BY WHOLE GENOME SEQUENCING
The molecular mechanisms for promotion vancomycin
resistance in VISA are attractive because of the widespread
incidence of VISA globally. The best way to identify the genetic
mutations in VISA is the whole genome sequencing of carefully
selected isogenic VSSA/VISA pairs or series from the clinic
or derived from the laboratory. Table 1 shows the mutations
identified by whole genome sequencing in hVISA/VISA
strains that may be responsible for the reduced vancomycin
susceptibility as compared with their progenitor VSSA. Between
the VISA strain JH9 and the VSSA strain JH1, the JH9 strain
had 35 point mutations in 31 genes (Mwangi et al., 2007). In
the laboratory, a VISA could be obtained by step-wise selection
with increasing concentrations of vancomycin in the culture
media to exhibit a vancomycin MIC level of>32 µg/mL, such as
VC40 [14], to the VRSA phenotype. Compared with its parent
strain RN42201mutS, VC40 had 79 mutations in 75 genes
(Berscheid et al., 2014), thereby suggesting that the mutations in
S. aureus genes may have cumulative effects that contribute to the
VISA phenotype. Most studies usually reveal no more than 10
mutations in isogenic VSSA/VISA pairs (Table 1). However, one
pair revealed that only one mutation (WalR-K208R) is enough
to convert a VSSA to VISA (Howden et al., 2011). From the
same parent VSSA strain JH1, two in vitro selected VISA isolates
JH1R1 and JH1R2 have different mutations when compared with
each other, which also differed from the in vivo VISA isolate JH2
(Vidaillac et al., 2013). These studies demonstrated that multiple
pathways are involved in the generation of VISA from VSSA.
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TABLE 1 | Mutations identified in hVISA/VISA strains comparied with the progenitor VSSA by whole genome sequencing.
VSSA/hVISA/VISA pairs
or series
Vancomycin
resistant
level (µg/mL)
Number of mutated
genes
Potential important mutations linked to VISA Year References
JH1/JH2/JH5/JH6/JH9 1/4/6/8/8 7/8/16/31 VraT-H164R, RpoB-D471Y+A473S+A477S+E478D
RpoC-E854K, PrsA-1C
2007 Mwangi et al., 2007
Mu3/Mu50 2/8 17 GraR-N197S, RpoB-H481Y, Fdh2-A297V, Sle1-167aa 2008 Neoh et al., 2008
Mu50/Mu50 0.5–1/6–7 10 GraR-N197S, VraS-2341C 2009 Cui et al., 2009
N3151IP/H14 1/2 1 VraS-S329L 2009 Katayama et al., 2009
ISP794/AR376 2/4 3 Stp1-Q121C, VraS-G45R, YjbH-K231C 2011 Renzoni et al., 2011
N315LR5P1/LR5P1-V3 1.5/4 2 WalK-1Q371, ClpP-1N 2011 Shoji et al., 2011
JKD6000/JKD6001 1/4 7 WalR-A96T 2011 Howden et al., 2011
JKD6004/JKD6005 2/4 1 WalR-K208R 2011 Howden et al., 2011
JKD6009/JKD6008 2/4 10 WalK-G223D, GraS-T136I 2011 Howden et al., 2011
JKD6021/JKD6023 1/4 8 WalK-V268F 2011 Howden et al., 2011
JKD6052/JKD6051 1/4 7 RpoB-H481Y, SarR-A68T 2011 Howden et al., 2011
SG-S/SG-R 1.5/3 5 VraT-Y220C, YycH-A165D, VraG-G551E 2012 Gardete et al., 2012
A5937/A5940 1.5/4 6 Stp1-1131C, H481Y 2012 Cameron et al., 2012
A6264/A6226 2/3 13 DltA-S38R, ArlS-381C 2012 Cameron et al., 2012
A6300/A6298 2/4 8 Drp35-N83S 2012 Cameron et al., 2012
A9635/A9636/A9637/
A9638/A9639
1/1/2/3/4 1/2/5/4 VraT-N74D, VraG-A580V 2012 Cameron et al., 2012
A8117/A8118/A8392 1/4/8 3/5 WalK-R263C-S273N, WalK-1Q371, TcaR-I69S-K95N,
RpoB-S1052L
2012 Cameron et al., 2012
VSSA-A1/VISA-A2 1/8 6 Stp1-E18D19-duplication 2012 Passalacqua et al., 2012
JH1/JH1R1 1/3 4 WalK-G223D 2013 Vidaillac et al., 2013
JH1/JH1R2 1/3 1 RpoB-R484C+N641K 2013 Vidaillac et al., 2013
Mu3/Mu3 derived 45 VISA
isolates
3/6–12 1–4 mutations affecting
a total of 48 genes
BPB4-S140N, TarO-P94L, Cmk-A20G, etc. 2013 Matsuo et al., 2014
D32/D52/D56/D83/D90/D109 Not shown 1/1/4/6/4 WalK-Q369R, WalK-M220I, VraG-1L294N295 2014 Van Hal et al., 2014
109/2482 1.5/3 11 RpoB-A477V+S529L, AgrC-L1931C 2014 Chen et al., 2014
RN42201mutS/VC40 1.5/64 75 VraS-L114S+D242G, WalK-I544M, MprF-H224Y,
RpoD-D201N
2014 Berscheid et al., 2014
MW-2/SV-1 2/16 or 1/16 5 WalK-G223D, TarO-frameshift 2015 Hu et al., 2015
CH1/CH2/CH3/CH4/CH5/
CH6/CH7
2/2/2/3/3/3/4 0/1/3/2/2/2 YycH-1C, MprF-S295L 2015 Chen et al., 2015
13136p−m+/13136p−m+
V5/13136p−m+V20
1/8/16 8/9 Stp1-A143G, TarO-L670F 2015 Hattangady et al., 2015
8 MR/VR pairs 1–2/8–32 50–172 in different
pairs
Diverse mutations in GraS, RpoB, RpoC, WalK and etc. 2015 Ishii et al., 2015
∆N, N-terminal deletion; ∆C, C-terminal deletion.
However, the diverse genetic mutations that contribute to the
altered cell wall structures and increased vancomycin resistance
in VISA need to be experimentally investigated.
EXPERIMENTALLY VERIFIED GENETIC
MUTATIONS IN CERTAIN GENES
RESPONSIBLE FOR VISA EVOLUTION
Although hundreds of single nucleotide polymorphisms (SNPs)
were discovered in VISA as compared with VSSA after the
whole genome sequencing of VSSA/VISA pairs or series, the
experimentally verified genetic mutations in certain genes
responsible for VISA evolution are still limited. Two methods
are usually used to functionally verify the role of a certain
mutation for the promotion of vancomycin resistance in VISA.
First, the mono- or bi-directional allelic exchange experiment
replaces the normal allele in VSSA with the mutated allele from
VISA or replaces the mutated sites in VISA with the normal
allele from VSSA; subsequently, the results are used to evaluate
whether the allele swapping is responsible for vancomycin
resistance. Some studies also conduct whole genome sequencing
of the allele-swapping strains to exclude other mutations during
experiments (Howden et al., 2011). The pKOR1 plasmid is
usually used in these allele-swapping experiments because it
has a counter-selection marker and can be used to generate
multiple allele swapping events (Bae and Schneewind, 2006).
For VISA clinical isolates that cannot be transformed, the
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mutations are reconstituted in well-defined laboratory strains,
such as N3151IP (Katayama et al., 2016). The constructed
strains are subject to vancomycin MIC determination, cell wall
thickness measurement with electron microscopy, and other
tests to verify and explore the mechanisms of gene mutation
in vancomycin resistance (Cameron et al., 2012). Another
genetic method is plasmid complementation with wild type or
mutated genes in VSSA or VISA isolates; however, the copy
number of plasmids cannot be precisely controlled, and the
results of complementation are usually not consistent with the
allele swapping results (Neoh et al., 2008; Matsuo et al., 2011).
Regardless, plasmid complementation is easy and labor-saving;
thus, this approach is still widely used for the verification of
loss-of-function mutations (Gardete et al., 2012; Matsuo et al.,
2014).
Allelic exchange techniques or complementation methods
have experimentally verified the four categories of genetic
mutations in VISA as summarized in Table 2. The first category
includes the genetic mutations in cell wall synthesis, hydrolysis,
or remodeling genes, including sle1 and msrR (Katayama
et al., 2016). The second group includes the genetic mutations
in metabolic genes, including cmk and fdh2 (Matsuo et al.,
2014; Katayama et al., 2016). The third category contains the
genetic mutations in transcription regulatory genes, including
yvqF/vraT-vraSR, graSR, walKR, and rpoB (Howden et al., 2014).
The fourth group has the genetic mutations in post-translational
modification genes, including stp1 and clpP (Shoji et al., 2011;
Cameron et al., 2012).
Mutated Genes for Cell Wall Synthesis,
Hydrolysis, and Teichoic Acid Synthesis
Accelerated cell wall synthesis and decreased autolysis
are alternative pathways for a thickened cell wall. Sle1 is
the hydrolase of N-acetylmuramyl-L-alanine amidase for
peptidoglycan biosynthesis and is involved in the cell wall
separation of S. aureus (Kajimura et al., 2005). Six mutations
were found in the VISA strain Mu50, but not in the VSSA strain
N3151IP; one of these mutations is sle1 (167aa). The deleted
67-aa polypeptide was localized to the LysM domain; thus, sle1
(167aa) is a loss-of-function mutation. The introduction of
sle1(167aa) into N3151IP drastically decreased the autolytic
activity and converted the induced cell wall thickening to
constitutive cell wall thickening (Katayama et al., 2016). Loss-of-
function mutations in cell wall hydrolysis genes, such as sle1, can
directly contribute to vancomycin resistance in VISA.
MsrR is a member of the LytR–CpsA–Psr (LCP) family,
which attaches wall teichoic acid (WTA) to the peptidoglycan
layer (Chan et al., 2013). The deletion of msrR reduced
WTA attachment and increased the cell size and aggregation
(Hübscher et al., 2009). WTA controls staphylococcal autolysis
by preventing the binding of autolysin to the assembled cell
wall, but not to the septum (Schlag et al., 2010). Expression of
msrR is increased by ≈four-fold upon vancomycin treatment
(Gardete et al., 2006). Overexpression of msrR in the VSSA
strain N315 reduced vancomycin and teicoplanin susceptibility
(Cui et al., 2005). The msrR (E164K) mutation is one of
six mutations identified in Mu50. The introduction of this
mutation into N3151IP increased the vancomycin resistance
(Katayama et al., 2016). The MsrR (E164K) mutation may
promote the attachment of WTA to the peptidoglycan layer
and further prevent the binding of autolysin to the assembled
cell wall, thereby decreasing cell wall autolysis and resistance to
vancomycin. However, whether the MsrR (E164K) mutation is a
gain-of-function mutation or a loss-of-function mutation is still
not resolved.
WTA is a highly negative charged polymer; the downregulated
production of WTA may decrease the negative charge of the
cell surface, thereby also contributing to vancomycin resistance
via electrical repulsion. The PBP4 is required for the highly
cross-linked peptidoglycan synthesis. PBP4 is localized at the
division septum; however, in the WTA synthesis gene tagO
deletionmutant, PBP4 was dispersed on the entire cell membrane
and could not function properly; thus, the degree of cross-
linking is decreased (Atilano et al., 2010). Furthermore, WTA
also controlled autolysin activity by influencing its localization
(Schlag et al., 2010). The loss of all the WTA caused by tagO
gene deletion enhanced autolysis (Schlag et al., 2010); however,
the inhibition of the late WTA synthesis by Targocil decreased
autolysis and strongly induced cell wall stress stimulon genes,
including pbpB and fmtA (Campbell et al., 2012). To obtain
a more comprehensive view of hVISA-to-VISA conversion, 45
high-level VISA isolates were selected by exposing Mu3 and its
related strains to 6 µg/mL vancomycin. Among the 45 VISA
isolates, 32 have a single mutation in 20 genes, thereby indicating
that these genes are directly involved in vancomycin resistance.
Among the 32 single mutations, six mutations were identified in
the tarO, tarA, and tarL genes (Matsuo et al., 2014). A frame
shift insertion mutation in tarO (llM) was also discovered in
the laboratory MW-2-derived VISA isolate SV-1 (Hu et al.,
2015). These studies collectively indicate that mutations or the
regulation of the WTA can contribute to vancomycin resistance
in VISA.
The lipoteichoic acid (LTA) is another negatively charged
polymer, which is linked to the cell membrane via a diglucosyl–
diacylglycerol (Glc2-DAG) linkage. In the LTA synthesis
pathway, glucose 6-phosphate (G6P) is converted to α-G1P
by PgcA, then α-G1P is activated by GtaB to generate UDP-
glucose; YpfP catalyzes the progressive addition of glucose to
diacylglycerol (DAG) from UDP-glucose to yield the LTA anchor
Glc2-DAG, which is flipped out by the LtaA protein. The loss
of function of PgcA, GtaB, and YpfP did not inhibit LTA
formation but altered the anchoring site and chain length of LTA
(Gründling and Schneewind, 2007), thereby influencing the cell
wall characteristics. In ∆ypfP, the autolysis activity is decreased
compared with the wild type (Fedtke et al., 2007). Interestingly,
one Mu3-derived VISA isolate has a C-terminal deletion of
GtaB, which lacks the catalytic core of GtaB. This loss-of-
function mutation in GtaB blocks the G6P to α-G1P conversion;
subsequently, G6P might be redistributed to the peptidoglycan
precursor synthesis. The bacterial two-hybrid approach revealed
that YpfP and LtaA can interact with numerous proteins involved
in cell division, peptidoglycan synthesis, or cell wall modification,
including FtsA, FtsW, PBP2, PBP4, and DltD (Reichmann et al.,
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TABLE 2 | Experimental verified mutations in VISA.
Target Year Mutation Sites Parental strain Vancomycin MIC
(µg/mL) changes
Methods References
VraTSR 2009 VraS-S329L N3151IP 1→2 pKOR1 mediated allele swapping Katayama et al., 2009
2012 VraT-Y220C SG-R 3→1.5 pGC2 mediated complementation
with wild type VraT
Gardete et al., 2012
2012 VraS-2341 SG-rev 1→3 pGC2 mediated complementation
with wild type VraS
Gardete et al., 2012
2014 VraS-L114S+D242G NCTC8325 1.5→4 Temperature-sensitive shuttle
vector pMAD mediated allele
swapping
Berscheid et al., 2014
GraSR 2008 GraS-T136I JKD6009 2→6 pKOR1 mediated allele swapping Howden et al., 2008
2008 GraR-N197S Mu3 2→4 pYT3 mediated overexpression Neoh et al., 2008
2011 GraS-T136I JKD6009 1.5→2 pKOR1 mediated allele swapping Howden et al., 2011
WalKR 2011 WalK-G223D JKD6009 1.5→3 pKOR1 mediated allele swapping Howden et al., 2011
2011 WalR-K208R JKD6004 or JKD6005 1.5→4 or 4→1.5 pKOR1 mediated allele swapping Howden et al., 2011
2011 WalK-1Q371 LR5P1 1.5→3 pKOR1 mediated allele swapping Shoji et al., 2011
2015 WalK-G223D MW2 2→4 pBTs mediated allelic replacement,
pBTs is derived from pBT2 and
pKOR1
Hu et al., 2015
ClpP 2011 ClpP-1N LR5P1 1.5→2 pKOR1 mediated allele swapping Shoji et al., 2011
Stp1 2012 Stp1 deletion A5937 1.5→3 pKOR1 mediated gene deletion Cameron et al., 2012
2012 Stp1-E18D19 duplication Strain A2 6–8→3 pOS1-Plgt mediated wild type
Stp1 complementation
Passalacqua et al., 2012
Cmk 2014 Cmk-A20G, CmK-T(-13)A Mu3 2→8, 3→8 pKOR1 mediated allele swapping Matsuo et al., 2014
2014 Cmk-A20G, CmK-T(-13)A Mu3p27V6–10 8→2, 8→3 Introduce the pND50-cmk plasmid
into the VISA isolates
Matsuo et al., 2014
VraS+GraR 2009 VraS-I5N+GraR-N197S Mu50 4→6 pKOR1-mediated allele swapping Cui et al., 2009
GraS+WalK 2011 GraS-T136I+ WalK-G223D JKD6009 1.5→4 pKOR1-mediated allele swapping Howden et al., 2011
GraR+RpoB 2011 GraR-N197S+RpoB-
H481Y
Mu3 2→6 pKOR1-mediated allele swapping Matsuo et al., 2011
WalK+ClpP 2011 WalK-1Q371+ ClpP-1N LR5P1 1.5→4 pKOR1 mediated allele swapping Shoji et al., 2011
VraS+Stp1+YjbH 2011 VraS-G45R+Stp1-
Q121C+YjbH-K231C
ISP794 2→4 Plasmid mediated gene
replacement and bacteriophage
transduction mediated triple
mutant construction
Renzoni et al., 2011
VraS+GraR+
RpoB+Fdh2+
Sle1+MsrR
2016 VraS-S329L+GraR-N197S
+RpoB-H481Y+Fdh2-
A297V+Sle1-167aa+
MsrR-E164K
N3151IP 1→12 pKOR1 mediated allele swapping Katayama et al., 2016
The vancomycin MIC levels determination methods are not consistent with each other in different studies.
2014). Overall, mutations in the synthesis of peptidoglycan,
WTA, and LTA or the remodeling processes can directly or
indirectly contribute to vancomycin resistance in VISA.
Mutated Genes Involved in Staphylococcal
Metabolism
Cell wall synthesis consumes high amounts of substrate and
energy. To build a thickened cell wall, the demand for cell wall
biosynthetic precursors is increased in VISA, which requires the
adjustment of cellular metabolism. VISA strains have impaired
acetate catabolism (Nelson et al., 2007). Genetically distinct
VISA strains are also associated with specific and reversible
metabolic alterations (Alexander et al., 2014). The abundance
of six metabolites from the urea cycle, the pentose phosphate
pathway, and the TCA cycle was altered in the JH series and the
SG series of VISA isolates (Alexander et al., 2014). These altered
metabolites are directly or indirectly linked to the biosynthesis
of cell wall precursors. Mutations in metabolic genes can directly
adjust cellular metabolism to support the cell wall synthesis.
The cmk gene product functions in the pyrimidine synthesis
pathway. A decrease in Cmk activity is expected to increase
UTP, which is required for the synthesis of a key peptidoglycan
intermediate UDP-GlcNAc. Two mutated forms of the cmk gene
have been introduced to Mu3, thereby converting the hVISA
isolate Mu3 to VISA isolates. One mutant is the Cmk-A20G
mutation; the other is a T-to-A mutation in the Shine-Dalgarno
(SD) sequence of Cmk (Matsuo et al., 2014). The Cmk-A20G
mutation decreased the Cmk activity, whereas a mutation in the
SD sequence decreased the translation of Cmk. A decrease in the
Cmk activity or Cmk protein levels probably caused increased
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vancomycin resistance by increasing the supply of cell wall
biosynthesis intermediate UDP-GlcNAc (Matsuo et al., 2014).
Cmk catalyzed the formation of cytidine diphosphate (CDP).
CDP is required for DNA/RNA synthesis and the formation
of the WTA synthesis precursor CDP-glycerol. Peptidoglycan
and WTA production depend on the lipid carrier undecaprenyl
phosphate; the Cmkmutation might suppress theWTA synthesis
pathway and enhance peptidoglycan synthesis.
Fdh2 is a putative formate dehydrogenase. The introduction
of an Fdh2-A297V mutation into N3151IP with the
aforementioned Sle1(167aa) converted the inducible cell
wall thickening to constitutive cell wall thickening (Katayama
et al., 2016). Therefore, mutations in metabolic genes can directly
influence cell wall synthesis and contribute to vancomycin
resistance in VISA. Several other mutated metabolic proteins
have been identified in VISA isolates, including proteins involved
in translation, nucleotide metabolism, amino acid biosynthesis,
and so on. These proteins may also directly adjust the cell
metabolism to support cell wall synthesis in VISA.
Mutated Genes for Transcriptional
Regulation
Among the cell wall synthesis or hydrolysis genes, the metabolic
genes are dynamically regulated by transcriptional factors and
other regulators. Hundreds of genes (≈10% of the whole
S. aureus genome) from several functional categories are
differentially expressed in VISA and VSSA. Previous studies
have directly identified mutations in transcriptional regulators
that may be the key players of vancomycin resistance in VISA
isolates. Most mutations in vraTSR, graSR, walKR, and rpoB have
been experimentally verified to be responsible for promoting
vancomycin resistance in VISA.
Mutation Activated VraTSR System
VraSR is characterized as vancomycin resistance-associated
because the VraSR operon is upregulated in the first reported
VISA isolate Mu50 (Kuroda et al., 2000). The operon
encompassing VraSR consists of four genes. The orf1 gene is
not required for cell wall stress stimulon, whereas VraT/YvqF–
VraS–VraR is a three-component system that regulates cell wall
stress stimulon (McCallum et al., 2011; Boyle-Vavra et al., 2013).
VraTSR positively modulates the cell wall biosynthesis pathway
in S. aureus (Kuroda et al., 2003). After induction by a cell
wall synthesis inhibitor, VraR activates the vra operon and 46
other genes for the cell wall stress regulon; some of these genes,
such as pbpB and fmtA, encode known or putative cell wall
synthesis proteins (Gardete et al., 2006). The use of an IPTG-
inducible promoter controlled pbpB revealed that the VraTSR
system might directly sense a cell wall synthesis step catalyzed by
PBP2 (Gardete et al., 2006). The consensus binding site of VraR
has been deduced (5′-ACT-N3-AGT-3′ or 5′-TGA-N3-TCA-3′)
(Belcheva et al., 2009). Chromatin immunoprecipitation showed
that the promoters of pbpB, murZ, and sgtB could directly be
binded by the VraR proteins, whereas direct binding was not
possible with fmtA (Sengupta et al., 2012). Upregulation of VraSR
and the VraSR-dependent cell wall stimulon is linked to the
increased vancomycin resistance phenotypes of several clinical
VISA isolates (Kuroda et al., 2000; McAleese et al., 2006; Kato
et al., 2008, 2010). By contrast, deletion of the vraSR operon
enhanced the sensitivity to vancomycin and other cell wall
targeting antibiotics (McCallum et al., 2011; Boyle-Vavra et al.,
2013).
The VraT-Y220C, VraS-I5N, VraS-S329L, and VraS-L114S-
D242G mutations have been experimentally associated with the
VISA phenotype. Whole genome sequencing of the susceptible
SG-S, the resistant strain SG-R, and the spontaneous revertant
strain SG-rev in an isogenic VISA-type series of ST8-USA300
isolates revealed that the VraT-Y220C mutation mediates
the vancomycin-resistant phenotype, whereas a premature
termination of the VraS at amino acid 234 reverts the
vancomycin-resistant phenotype (Gardete et al., 2012). VraS has
347 amino acids but the histidine kinase domain is lost when
shortened to 234 amino acids. These data suggest that VraT is
a negative regulator of VraSR, and VraT-Y220C is a loss-of-
function mutation. Complementation of the VISA isolate with
wild-type vraT can revert the vancomycin-resistant phenotype,
whereas complementation of the reverted VSSA isolate with
wild-type VraS can promote the vancomycin-resistant phenotype
(Gardete et al., 2012).
The introduction of the VraS-I5N or VraS-S329L mutation
into a VSSA isolate increased vancomycin resistance (Cui et al.,
2009; Katayama et al., 2016). The reconstitution of the VraS-
L114S-D242G allele into the VSSA strain NCTC8325 increased
resistance to vancomycin (Berscheid et al., 2014). Furthermore,
the cell wall stress regulon controlled by VraSR is upregulated in
these VISA isolates. All these studies indicate that mutations in
the VraTSR system cause its activation and the upregulation of
the cell wall stress regulon, thereby increasing cell wall synthesis
and vancomycin resistance in VISA.
Mutation Activated GraSR System
The GraSR system is a two component system (TCS) associated
with glycopeptide resistance (Cui et al., 2005). The GraSR
proteins interact with GraX and the VraFG ABC transporter to
form a five-component system for cationic antimicrobial peptide
(CAMP) resistance (Falord et al., 2012a). The GraSR system
is required for CAMP resistance, such as resistance to human
defensins. Resistance to CAMPs is mediated by the D-alanylation
of cell wall teichoic acids by the DltABCD enzymes and the
MprF-dependent lysylination of phoshpatidylglycerol (Ernst and
Peschel, 2011). GraR can self-dimerize; upon phosphorylation
by GraS on the D51 residue, GraR binds to the promoters
of vraFG, dltABCD, and mprF to initiate their transcription.
A highly-conserved 10 base pair palindromic sequence (5′-
ACAAATTTGT-3′) is the putative GraR-binding site, which is
located in the upstream sequences ofmprF, dltABCD, and vraFG
genes.
The GraSR system is upregulated in VISA isolates (Cui et al.,
2005). The deletion of GraSR or VraFG caused hypersensitivity to
vancomycin, increased autolysis, and produced a more negative
net surface (Meehl et al., 2007). The Mu50 strain has a GraR-
N197S substitution; the introduction of this substitution on
the plasmid pYT3 vector can convert the hVISA strain Mu3
to achieve high vancomycin resistance similar to that of the
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VISA strain Mu50 (Neoh et al., 2008). However, the GraR-
N197S substitution on the pYT3 vector is a high-copy version;
the introduction of a single copy of GraR-N197S into Mu3
did not increase vancomycin resistance to the level of VISA
(Matsuo et al., 2011). Thus, the GraR N197S only has a marginal
effect on vancomycin resistance. The GraR-N197S substitution
and the RpoB-H481Y mutation can convert Mu3 to the full
vancomycin resistance level of Mu50 (Matsuo et al., 2011).
The GraS-T136I mutation can also increase the vancomycin
resistance levels (Howden et al., 2008). However, GraS-T136I
alone is not sufficient to convert VSSA to the full vancomycin
resistance of VISA. The combination of GraS-T136I and WalK-
G223D is required to achieve the full vancomycin resistance level
of VISA (Howden et al., 2011). All these studies indicate that the
activated GraSR system can increase vancomycin resistance by
upregulating the dltABCD andmprF genes.
Mutation Downregulating the WalKR System
Expression or Activity Contributed to Vancomycin
Resistance in VISA
As the only essential TCS for the viability of S. aureus, theWalKR
system connects cell wall biosynthesis with cell division. WalK
has two transmembrane helices and a C-terminal kinase domain.
The N-terminal Per–Arnt–Sim (PAS) domain may be involved
in signal sensing. WalR controls the expression of its regulon by
forming a head-to-head dimer of the receive domains, which is
paired with a head-to-tail dimer of the winged helix-turn-helix
motifs that bind to the tandem DNA repeats of the binding site
(Dubrac et al., 2008). The potential consensus DNA recognition
sequences of WalR consist of two hexanucleotide direct repeats
(5′-TGT(A/T)A(A/T/C)-N5-TGT(A/T)A (A/T/C)-3′) (Dubrac
et al., 2008). In VISA isolates, the expression levels of altA,
sle1, lytM, and several genes encoding CHAP domain-containing
proteins were down-regulated. The genes for AtlA, Sle1, LytM,
and the CHAP domain-containing proteins are repressed by
TCSs, such as LytSR and ArlSR, and positively regulated by
the WalKR. Promoter analysis demonstrated that atlA, sle1, and
lytM have the consensus sequence for WalR binding. Expression
analysis by WalKR starvation or the constitutive form of WalR
supported that atlA, sle1, and lytM are directly transcribed by the
WalKR system in S. aureus (Dubrac et al., 2007; Delauné et al.,
2012).
Two studies examined an IS256 insertion into the walKR
promoter and revealed that the upregulation ofwalKR expression
will decrease resistance levels to vancomycin, whereas the
downregulation of walKR expression will increase the resistance
levels of vancomycin (Jansen et al., 2007; McEvoy et al., 2013).
Jansen et al. (2007) compared two VISA isolates SA137/93A
(MIC= 8µg/mL) and SA137/93G (MIC= 12µg/mL) and found
that SA137/93A has an IS256 insertion in the predicted promoter
region. However, this IS256 insertion generates a potentially
stronger promoter, which upregulated the walKR expression
of SA137/93A; thus, the upregulation of WalKR produces
low levels of vancomycin resistance (8 vs. 12µg/mL), thereby
indicating that walKR is a negative regulator of vancomycin
resistance (Jansen et al., 2007). An IS256 insertion to the 5′-
untranslated region (5′-UTR) of walKR reduced the expression
of walKR by ≈50%; the downregulation of walKR will increase
the vancomycin resistance level of VSSA isolates (McEvoy et al.,
2013). The removal of IS256 could revert the VISA phenotype to
VSSA, thereby confirming that the reduced expression of WalKR
induced the VISA phenotype. These studies collectively suggest
that the downregulation of walKR expression contributes to the
development of vancomycin resistance in VISA.
Several studies examined the mutated forms of WalKR in
vancomycin resistance of VISA. In a laboratory-derived VISA
strain, Shoji et al. (2011) found that the walK∆Q371 allele
influences vancomycin resistance, but this allele is not sufficient
for full vancomycin resistance. However, the walKR mutation
was the most frequent in VISA strains. Genome sequencing of
five VSSA/VISA pairs revealed that the VISA in four of these pairs
carried mutations in the WalKR system (Howden et al., 2011).
Subsequently, allelic replacement demonstrated that WalK-
G223D with GraS-T136I could convert VSSA to full intermediate
vancomycin resistance similar to VISA. The allelic replacement
of WalR-K208R can also convert VSSA to full intermediate
resistance to vancomycin (Howden et al., 2011). Howden et al.
(2011) proposed that mutations in WalKR may downregulate
its activity. SV-1 is a laboratory-derived VISA strain from CA-
MRSA MW2 with the same WalK-G223D mutation as the
clinically-isolated strain JKD6008 (Hu et al., 2015). The WalK-
G223D mutation had decreased autophosphorylaton of WalK,
thereby reducing the phosphorylation of the WalR response
regulator and decreasing the binding activity of WalR to the
altA promoter based on the electrophoretic mobility shift assay
(Hu et al., 2015). Therefore, the downregulated expression or
impaired activity of the WalKR system can mediate vancomycin
resistance in VISA by downregulating the expression of autolysin
genes.
Mutation Altered the Activity of RpoB
The rpoB gene encodes the β subunit of RNA polymerase, which
is active in catalysis. Mutations in RpoB might influence the
transcriptional activity of the whole RNA polymerase. The most
extensively studied mutation of RpoB in VISA is the H481Y
substitution. The introduction of a single copy of the GraR
N197S into the Mu3 is not enough to achieve the vancomycin
resistance level of the VISA isolate Mu50 (Matsuo et al., 2011).
Targeted sequencing of the rifampicin resistance-determining
region (RRDR) showed that Mu50 has an H481Y mutation at
RpoB. Genetic swapping studies confirmed that the RpoB-H481Y
mutation is responsible for the emergence of the VISA phenotype
(Matsuo et al., 2011). The RpoB-H481Y mutation causes global
transcriptional changes, which promote antimicrobial peptide
resistance, with attenuated virulence in a murine bacterimia
model (Gao et al., 2013). Mutations in other subunits of RNA
polymerase such as RpoC or RpoD, have also been found
in VISA isolates (Matsuo et al., 2014). The ST239-MRSA-III-
t030 clone is prevalent in China; most ST239-MRSA-III-t030
strains harbor double substitutions in RpoB (H481N+L466S)
that confer resistance to rifampicin, but not to vancomycin
(Zhou et al., 2012; Shang et al., 2016). Therefore, the RpoB-
H481N mutation may not confer vancomycin resistance similar
to that of the RpoB-H481Y mutation; otherwise, a second
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mutation (L466S) could compensate for the effect of H481N
on vancomycin resistance. This hypothesis is worthy of further
investigation.
SarA/MgrA Family Proteins in VISA
The staphylococcal accessory protein A (SarA) family of global
regulatory proteins control virulence, antibiotic resistance, cell
wall synthesis, and other defensive pathways. SarA and MgrA
are negative regulators of murein hydrolases (Ingavale et al.,
2003). SarV is repressed by SarA and MgrA and is involved
in autolysis (Manna et al., 2004). The sarA deletion mutant
displayed enhanced resistance to vancomycin (Sun et al., 2012).
Moreover,mgrA overexpression increased vancomycin resistance
in S. aureus (Cui et al., 2005). An A68T mutation in SarR was
identified in a VISA clinical isolate; however, this mutation has
not been experimentally verified (Howden et al., 2011).
In the constitutive WalR mutant, the expression of sarS, sarT,
and icaR was repressed by the WalKR system (Delauné et al.,
2012). The sarS and sarR expression is also positively controlled
by GraSR (Falord et al., 2012b). The msaABCR operon can
positively regulate the expression of sarA to promote biofilm
formation and enhance virulence while negatively regulating
autolysis in S. aureus (Sambanthamoorthy et al., 2006). The
inactivation of the msaABCR operon in three different VISA
isolates increased the susceptibility to vancomycin and reduced
the vancomycin-binding capacity (Samanta and Elasri, 2014).
These studies collectively indicate that the SarA family proteins
are crucial regulators in VISA.
CcpA and CcpE, Potential Regulators in VISA
The catabolite control protein A (CcpA) is the major regulator of
carbon catabolite repression (CCR). In the presence of glucose or
other preferred carbon sources, CcpA forms a complex with S46-
phosphorylated Hpr protein. The CcpA–Hpr-S46(P) complex
binds to the catabolite responsive element (cre) sequences
of diverse genes to activate or repress their expression. The
expression of ccpA is negatively self-regulated (Leiba et al., 2012).
The expression of several genes is affected by ccpA inactivation
in the absence of glucose, thereby indicating that the function
of CcpA is not restricted to CCR and includes virulence and
antibiotic resistance regulation (Seidl et al., 2009). CcpA can
also regulate numerous virulence factors (Seidl et al., 2006).
The expression of the urease operon is downregulated in ∆ccpA
compared with the wild type, which is consistent with results of
the urease activity assay (Seidl et al., 2009).
Transcription analysis revealed that the phosphorylation
transfer system (PTS) of different carbon sources is usually
influenced by antibiotic treatment or the vraSR, graSR, and
walKR systems. The expression of PTS genes is directly controlled
by the CcpA protein. CcpA represses the tricarboxylic acid (TCA)
cycle, which is required for the full oxidation of glucose; CcpA
also regulates the genes involved in the glycolytic pathway and
metabolism (Seidl et al., 2009). Although the CcpA mutation
was not observed in VISA isolates, the deletion of ccpA reduced
teicoplanin resistance levels in a glycopeptide-intermediate S.
aureus strain (Seidl et al., 2006). The altered central metabolism
in VISA can also regulate CcpA activity, which can be fine-
tuned by small molecule effectors, such as G6P and fructose
1,6-bisphosphate (FBP), which both enhance the DNA-binding
activity of the CcpA–Hpr-S46(P) complex (Schumacher et al.,
2007). However, the G6P and FBP levels significantly decreased
in the ∆stp1 strain, which has increased vancomycin resistance
(Liebeke et al., 2010). Mutations in metabolic genes or the
altered central metabolism in VISA isolates might control gene
expression via the CcpA protein.
Catabolite control protein E (CcpE) can also affects the
central metabolism as well as virulence. CcpE is the first positive
regulator of TCA cycle reported in S. aureus by activating the
expression of acotinase gene (citB) (Hartmann et al., 2013). In
addition, CcpE positively regulate the expression of acetyl-CoA
carboxylase (AAC) gene, while AAC catalyzes the committed step
in fatty acid biosynthesis (Ding et al., 2014). On the other hand,
CcpE negatively control the expression of many virulence genes
(Ding et al., 2014). Intriguingly, CcpE is allosterically activated
by the TCA cycle intermediate citrate (Ding et al., 2014). The
altered central metabolism observed in VISA might control gene
expression via the CcpE protein and vice versa, though no genetic
mutations occured in CcpE have been observed in VISA isolates.
Mutated Genes for Protein
Phosphorylation or Degradation Mediate
Vancomycin Resistance in VISA
Aside from transcriptional control, the protein phosphorylation
and degradation processes are widely used as regulatory
mechanisms. The reversible phosphorylation and
dephosphorylation of proteins by Stk1/Stp1 have important
roles in diverse cellular processes of S. aureus (Ohlsen and
Donat, 2010). Moreover, the ATP-dependent ClpP protease
involved in intracellular proteolysis plays important roles in
stress response, metabolism and cell wall synthesis (Frees et al.,
2014). Mutations in stp1 or clpP have been associated with
vancomycin resistance in VISA.
Mutations in stk1/stp1
The Stk1 (PknB)/Stp1 (PP2C) pair is a eukaryotic-like Ser/Thr
kinase/phosphatase system in bacteria. Stk1 and Stp1 are
usually found to function together to regulate the reversible
phosphorylation of substrates. Stk1 is also a substrate of Stp1
(Débarbouillé et al., 2009). In S. aureus, Stk1 is a membrane-
bound protein, whereas Stp1 is a cytosolic protein. The N-
terminal domain of Stk1 inside the cytoplasm is associated
with kinase activity, whereas the C-terminal domain of Stk1
has three penicillin-binding protein and serine/threonine kinase-
associated (PASTA) domains, which are hypothesized to respond
to cell wall signals. Biophysical and structural studies revealed
the direct interactions of the PASTA domain of Stk1 with
muropeptides (Ruggiero et al., 2012). The deletion of stk1,
stp1, or both can influence cell wall structure and antibiotic
susceptibility. The stp1 deletion mutant displayed a thickened
cell wall and increased resistance to lysostaphin (Beltramini et al.,
2009). Furthermore, the stk1 deletion mutant was more virulent
than the parental strain in a murine cutaneous infection model
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(Tamber et al., 2010). By contrast, the stp1 deletion mutant was
avirulent in a mouse sepsis model (Cameron et al., 2012).
Three studies examined the role of protein phosphatase Stp1
in VISA isolates or in isolates with decreased susceptibility
to teicoplanin (Renzoni et al., 2011; Cameron et al., 2012;
Passalacqua et al., 2012). In the three studies, the loss of stp1
function via the deletion of stp1 or a premature stop codon
increased the vancomycin and teicoplanin resistance levels. A
two amino-acid insertion mutation at the highly conserved
metal-binding domain of Stp1 was discovered by whole genome
sequencing between the VISA isolate and its parental VSSA
isolate from a single patient with endocarditis (Passalacqua et al.,
2012). The two amino-acid insertion mutation may lead to
the inactivation of Stp1 activity. The complementation of the
VISA isolate with a wild copy of Stp1 reduced the vancomycin
MIC (Passalacqua et al., 2012). Comparative genomics of a
collection of VSSA/VISA isogenic pairs revealed the loss-of-
function mutations in the stp1 gene of VISA isolates. The
construction of an stp1 deletion mutant showed that Stp1 is
involved in both vancomycin resistance and virulence (Cameron
et al., 2012). A premature stop codon mutation and two other
mutations were identified in a laboratory-derived teicoplanin-
resistant S. aureus isolate. Complete genetic analysis revealed that
the loss-of-function mutation in Stp1 contributed to teicoplanin
and vancomycin resistance (Renzoni et al., 2011).
The transcriptome analysis of stk1 deletion strains revealed
that Stk1 can regulate many genes involved in nucleotide
biosynthesis, cell wall metabolism, and autolysis (Donat et al.,
2009). Several studies demonstrated that Stk1/Stp1 can cross
talk with TCSs and other transcription factors (Table 3). VraR
is a substrate of Stk1 (Ling et al., 2014); the phosphorylation
of VraR at multiple sites (T106, T119, T175, and T178) by
Stk1 negatively regulates its dimerization formation and DNA-
binding activity, which can downregulate the VraSR system.
Stk1/Stp1 can also regulate protein cysteine-phosphorylation of
the SarA/MgrA family (SarA, MgrA, and SarZ) global regulators,
which are involved in virulence and antibiotic resistance (Sun
et al., 2012). In the stp1 mutant, the phosphorylation state
of SarA is increased. However, the binding to promoters is
lost, thereby indicating that SarA phosphorylation attenuates
its transcriptional activity. Another study revealed that CcpA
is a substrate of the Stk1/Stp1 pair; the phosphorylation of
CcpA (T18, T33) also decreased its DNA-binding activity (Leiba
et al., 2012). By contrast, GraR can be phosphorylated by
Stk1 at T128, T130, and T149 in the DNA-binding domain,
but phosphorylation at these sites increased the DNA-binding
activity of GraR (Fridman et al., 2013). Consequently, the
expression of dltABCD operons is upregulated; these operons
encode proteins to catalyze the D-alanyl esterification of the
polyglycerol phosphate LTA and the polyribitol phosphate WTA
(Fridman et al., 2013). The increased positive charge of LTA
and WTA play important roles in exclusion of the cationic
antibiotics such as vancomycin (Fridman et al., 2013). The
stage V sporulation protein G (SpoVG) homolog of S. aureus
modulates virulence factor synthesis and antibiotic resistance.
The deletion of spoVG reduced teicoplanin and vancomycin
resistance; although the level of resistance to teicoplanin was
more pronounced than that to vancomycin (Schulthess et al.,
2009). SpoVG can directly bind to the putative promoters of lytN,
femA, and lytSR, and modulates oxacillin resistance in MRSA
strain N315 (Liu et al., 2016). A recent study found that SpoVG
is also subject to phosphorylation by Stk1; the Stk1-mediated
phosphorylation markedly enhanced the DNA-binding activity
of SpoVG (Bischoff et al., 2016). Therefore, the loss of stp1
will cause the irreversible phosphorylation of several important
transcription factors involved in vancomycin or teicoplanin
resistance and virulence.Whether CcpE is regulated by Stk1/Stp1
awaits further investigation.
Metabolomic studies found that the levels of cell wall synthesis
precursors were significantly changed in the S. aureus stk1 or
stp1 mutant (Liebeke et al., 2010). For instance, the levels of
fructose-1,6-bisP, glucose-6-P, and fructose-6-P are significantly
decreased in the stp1 deletion mutant as compared with the wild
type (Liebeke et al., 2010). This study indicated that metabolic
enzymes might also be subjects for phosphorylation by Stk1. Stk1
can directly phosphorylate adenylosuccinate synthase (PurA)
and downregulate its enzymatic activity (Donat et al., 2009).
Autoinducer-2 (AI-2) is an important signaling molecule in
quorum-sensing system of S. aureus, its synthase (LuxS) can
be inactivated by Stk1 phosphorylation at T14 (Cluzel et al.,
2010). The substrates of Stk1/Stp1 in S. aureus are summarized
in Table 3.
Mutations in Genes Encoding Proteolytic Proteins
ClpP is a proteolytic subunit of the ATP-dependent Clp protease.
A core proteolytic chamber is formed by ClpP and flanked by
several ATPases, including ClpC, ClpX, ClpB, and ClpL. The
ATPases determine substrate specificity and perform chaperon
activities. The ClpP and Clp ATPases are involved in stress
response, virulence, metabolism, and antibiotic resistance (Frees
et al., 2014).
A 144 bp deletion of clpP caused the loss-of-function of ClpP
with the WalK Q371 single amino acid deletion, which was
found to mediate vancomycin resistance in a laboratory-derived
VISA isolate (Shoji et al., 2011). The deletion of ClpP affects
the expression of several important regulatory genes, including
agr, sigB, sarT, and walKR (Shoji et al., 2011). Proteomics has
revealed that numerous proteins are substrates of ClpC or ClpP
(Feng et al., 2013; Graham et al., 2013), including proteins
involved in cell wall synthesis, hydrolysis, and transcriptional
regulation (Table 4). The cell wall synthesis proteins, such as
PBP2, FemA, and FemB, and the autolysins, including Sle1
and Atl, can be hydrolyzed by ClpP; however, accumulated
autolysins are catalytically inactive in the ClpP mutant, and
the underlying mechanisms remain elusive (Feng et al., 2013).
Transcription factors, such as CcpA,HprK (co-repressor of CcpA
kinase), and CodY, are also substrates of ClpP or ClpC in S.
aureus (Frees et al., 2014). The effects of proteolytic proteins,
such as ClpP, on vancomycin resistance in VISA may occur via
their regulational roles on the transcription factors. By contrast,
ClpC, ClpP, and ClpB can also be repressed by the GraSR
system (Falord et al., 2012b). However, ClpB is activated by
the WalKR system, whereas ClpC is repressed (Delauné et al.,
2012).
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TABLE 3 | Summary of substrates of Stk1/Stp1 determined in S. aureus.
Substrates Function Phosphorylation site(s) Effects of phosphorylation References
VraR Vancomycin-resistance-associated response
regulator VraR
Thr106, Thr119, Thr175, Thr178 Decreased DNA-binding properties Canova et al., 2014
SarA, SarA/MgrA family transcriptional regulators Cys9 Decrased DNA binding activity Sun et al., 2012
MgrA, SarA/MgrA family transcriptional regulators Cys12 Decrased DNA binding activity Sun et al., 2012
SarZ SarA/MgrA family transcriptional regulators Cys13 Decrased DNA binding activity Sun et al., 2012
CcpA Catabolite control protein A Thr-18, Thr-33 Electrophoretic mobility shift assays
demonstrated that the CcpA DNA
binding activity was completely
abrogated for the phosphorylated CcpA
Leiba et al., 2012
GraR a two-component system involved in
resistance to cationic antimicrobial peptides
Thr128, Thr130, Thr149 Increased DNA binding activity Fridman et al., 2013
SpoVG Modulator of virulence factor synthesis and
antibiotic resistance
Thr4, Thr13, Thr24, Ser41 Enhanced the DNA binding activity Bischoff et al., 2016
LuxS Autoinducer-2 synthase Thr14 The enzymatic activity of the
phosphorylated isoform of LuxS was
abrogated compared to that of
non-phosphorylated LuxS
Cluzel et al., 2010
PurA Adenylosuccinate synthase involved in
synthesis of AMP
Not determined Decreased enzymatic activity of PurA Donat et al., 2009
TABLE 4 | Summary of ClpP or ClpC substrates related to vancomycin
resistance in VISA.
Protein Function
name
Sle1 Autolysin precursor
Atl Bifunctional autolysin precursor
Glck Glucokinase
GlmS Glucosamine–fructose-6-phosphate aminotransferase, isomerizing
GlmM Phosphoglucosamine mutase
MurC UDP-N-acetylmuramate–alanine ligase
MurG UDP-glucose diacylglycerol glucosyltransferase
MurI Glutamate racemase
MurE UDP-N-acetylmuramoylalanyl-d-glutamate–2,6-diaminopimelate ligase
FemA Formation of the pentaglycine cross bridge
FemB Formation of the pentaglycine cross bridge
Pbp2 Penicillin-binding protein 2, peptidoglycan cross linking
SigA RNA polymerase sigma factor
RpoA DNA-directed RNA polymerase, alpha subunit
RpoB DNA-directed RNA polymerase, beta subunit
CodY GTP-sensing transcriptional pleiotropic repressor
SaeR Response regulator SaeR
CcpA Catabolite control protein A
AgrA Staphylococcal accessory gene regulator A
RsbW Serine-protein kinase RsbW
Other Genes Involved in Vancomycin
Resistance
The airSR genes encode an important TCS involved in cell
wall biosynthesis and vancomycin resistance. The deletion of
airSR showed reduced viability of S. aureus in the presence of
vancomycin (Sun et al., 2013). The teicoplanin resistance factor A
(TrfA) also affects vancomycin and oxacillin resistance (Renzoni
et al., 2009). TrfA is a homolog of the MecA adaptor protein
of the ClpC ATPase and is involved in the proteolysis. The
transcription control of trfA is mediated by the thiol/oxidative
stress global regulator Spx (Jousselin et al., 2013). The proteolytic
degradation of Spx is governed by the YjbH protein, which is
an adaptor protein of the ClpXP protease that was mutated in a
laboratory-derived VISA isolate (Renzoni et al., 2011). Thus, the
YbjH–Spx–TrfA cascade is important for vancomycin resistance
in VISA isolates. The tcaA gene encodes a transmembrane
protein, which is in the same operon as tcaB and tcaR. TcaB
is a multidrug eﬄux pump, whereas TcaR is a transcriptional
regulator of virulent determinants. The inducible expression of
tcaA is dependent on VraSR (Chen et al., 2016). The inactivation
of tcaA can increase the vancomycin resistance of S. aureus
isolates (Maki et al., 2004).
CONCLUSIONS AND A PROPOSED
MODEL
Given the increasing use of vancomycin, VISA emerged in the
mid or late 1980s and has become a global health threat. Although
the mechanisms for the promotion of vancomycin resistance in
VISA are diverse, VISA exhibit several common characteristics,
such as thickened cell walls, reduced autolysis, and attenuated
virulence. The diverse mutations in certain genes identified in
VISA imply the multiple complicated evolutionary pathways
for VISA. We proposed a multiple-hit model for vancomycin
resistance in VISA (Figure 3). On one hand, the mutated and
constitutively activated VraTSR and GraSR systems increased the
transcription of genes for cell wall synthesis and modification,
including pbpB, dltABCD, and mprF, thereby increasing the
cell wall biosynthesis and the D-alanyl esterification of LTA
and WTA. The mutated and actively downregulated WalKR
system decreased the expression of autolysins and PBP4, thereby
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FIGURE 3 | Molecular events in VISA. Key regulatory proteins and cell wall synthesis processes and their enzymes related to vancomycin resistance in VISA. WTA,
wall teichoic acid; LTA, lipoteichoic acid; Glc, glucose; GlcN-6-P, glucosamine-6-phosphate; GlcNAc, N-acetylglucosamine; MurNAc, N-Acetylmuramic acid; DAG,
diacylglycerol.
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decreasing autolysis and the muropeptide cross-linking in VISA.
The mutation and loss of function in Stp1 led to irreversible
phosphorylation of several transcriptional factors by Stk1, such
as GraR, VraR, CcpA, and SarA, which will directly or indirectly
influence vancomycin resistance in VISA. The mutation and loss
of function in ClpP upregulated the transcription factors and
cell wall synthesis proteins, such as PBP2, FemA, and FemB.
Mutations occurred in the cell wall synthesis or hydrolysis
genes, such as msrR and sle1, which could directly influence
cell wall synthesis; mutations in the metabolic genes, such as
fdh2, could adjust the cell metabolism to support cell wall
synthesis precursors. These mutated genes collectively influenced
the balance between cell wall synthesis and hydrolysis, which
would lead to cell wall thickening. The thickening of the cell wall
and its decreased cross-linking undoubtedly providemore free D-
Ala–D-Ala residues. Thus, to arrive at the cell wall synthesis site,
namely, the division septum, most of the vancomycin molecule
might be trapped, thereby elevating the vancomycin resistance in
VISA. On the other hand, the alteration of central metabolism
(TCA) might enhance the lipid cycle in VISA by regulating
the CcpE protein, which promotes the nascent peptidoglycan
biosynthesis, as well as the synthesis of LTA andWTA.Mutations
in metabolic genes, such as cmk, caused the downregulation of
LTA and WTA synthesis as well as increased the vancomycin
resistance in VISA.
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